Azzad Asset Management Inc /Adv Alnylam Pharmaceuticals, Inc. Transaction History

Azzad Asset Management Inc /Adv

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Apr 01, 2024	SELL	$170.77 - $211.65 $465,348 - $576,746	-2,725 Closed	0 $0
Q2 2023 Apr 01, 2024	BUY	$185.01 - $212.05 $2,035 - $2,332	11 Added 0.41%	2,725 $518 Million
Q1 2023 Apr 01, 2024	BUY	$182.66 - $235.53 $3,470 - $4,475	19 Added 0.71%	2,714 $544 Million
Q4 2022 Apr 01, 2024	BUY	$185.53 - $241.31 $4,452 - $5,791	24 Added 0.9%	2,695 $641 Million
Q3 2022 Apr 01, 2024	BUY	$138.54 - $232.0 $692 - $1,160	5 Added 0.19%	2,671 $535 Million
Q2 2022 Apr 01, 2024	BUY	$120.42 - $169.29 $7,466 - $10,495	62 Added 2.38%	2,666 $389 Million
Q1 2022 Apr 01, 2024	SELL	$127.18 - $173.91 $10,555 - $14,434	-83 Reduced 3.09%	2,604 $425 Million
Q4 2021 Apr 01, 2024	BUY	$159.56 - $209.29 $428,737 - $562,362	2,687 New	2,687 $456 Million

644

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.3B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Azzad Asset Management Inc /Adv, based on Form 13F filings with the SEC.

Stay updated on Azzad Asset Management Inc /Adv with notifications on news.